Independence Resources Plc (SNKTY)

[BioSpecialist]

More EU Approvals coming soon ::

Market Cap of 10 M$ is a Joke ...
Cash 13 M$


The Company reported that there continues to be great interest in Invicorp® for the European Market and that the Company is diligently working to restore an out-of-stock situation due to its former licensee, Ardana BioScience Limited, entering receivership. Senetek expects to have finished product manufactured in the fourth quarter of 2009 and, thus, to begin receiving corresponding revenues for Named Patient Supplies in the UK and commercial sales in Denmark. The Company noted a recent addition to the general approval process in Europe that could impact future sales of Invicorp, creating a potential opportunity to accelerate approval in some countries such as Turkey, a country with a population of more than 36 million males. Invicorp is a highly safe and effective treatment for erectile dysfunction ("ED") that has received marketing authorization in Denmark and authorization for Named Patient Supply in the UK.

"The second quarter saw the Company take a variety of actions aimed at preparing for sales growth as we initiated the rollout of clinically-proven PyratineXR, our next generation Cytokinin-based skincare technology, into the marketplace," said Frank Massino, Chairman and CEO, Senetek PLC. "We enter the second half of the year with focus and momentum as we launch our first marketing campaign for PyratineXR, which has been shown to be highly beneficial for all skin types, while being ideal for sensitive skin caused by inflammatory skin conditions such as rosacea and acne, which result in facial redness in millions of people."

On July 22, 2009, the Company announced that PyratineXR is now available nationwide through select dermatologists and other physicians. The launch is being supported by conventional and new line media advertising in select markets nationwide. To view copies of the ads, visit http://www.senetekplc.com/ads. The Company expects to launch a comprehensive new website for PyratineXR, incorporating product information, educational resources and e-commerce capabilities among other features, during the third quarter at www.PyratineXR.com.

During the second quarter, a clinical study entitled "Topical PRK-124 (0.125%) Lotion for Improving the Signs and Symptoms of Rosacea," was published in the Journal of Drugs in Dermatology, a prestigious peer-reviewed dermatological publication (May 2009). The 12-week, open-label study concludes that PyratineXR (0.125% furfuryl tetrahydropyranyladenine) improved skin barrier function and the appearance of erythema (redness) and lesions (pustules and papules) associated with mild-to-moderate rosacea during 12 weeks of treatment.

In the latter stages of the quarter, Senetek opened its new Customer Care Center in Brentwood, TN to support the national rollout of PyratineXR as well as Pyratine-6. The Customer Care Center, located outside of Nashville, provides doctors (dermatologists, plastic surgeons, etc.) and others who provide PyratineXR and Pyratine-6 to consumers an on-call resource to answer any questions related to the products and for sales, distribution and fulfillment. Consumers can call the Customer Care Center to find Pyratine products in their hometowns, to have questions answered and to place orders. The Customer Care Center is led by Mark Ryals, Director of Customer Service, who brings nearly 25 years of pharmaceutical and related customer service and sales experience to Senetek. Ryals spent 12 years working with GlaxoSmithKline's dermatology portfolio.

In early June, Senetek announced a six year extension of existing rights under its agreement with the Czech Republic Institute of Experimental Botany to receive exclusive global licenses, for all applications, to any cytokinin developed, in-licensed or otherwise acquired by the Institute and the right to co-exploit with the Institute any cytokinins that Senetek does not elect to in-license. Senetek also has a right of first refusal before the Institute can license any of its non-cytokinin compounds to any third party for cosmeceutical or anti-aging dermatological applications. In addition, a new group of compounds, "supercytokin plus", has been added to the agreement. The Institute will also perform enhanced research activities in the areas of pre-selective assay, development of analytical methods, stability testing, large scale synthesis and molecular mechanism of action. Visit the Institute's website at www.ueb.cas.cz.

Clinical studies demonstrate that PyratineXR is an anti-aging compound that can help "Beat Red" with 67% less redness, 84% smoother skin and 41% more moisture. Physician-strength PyratineXR is clinically proven to relieve redness (erythema), soothe irritation, increase moisture and repair damaged skin quickly and effectively. Clinical studies have demonstrated that PyratineXR significantly reduces the appearance of lesions (papules and pustules), spider veins and dark spots. In addition, PyratineXR improves skin texture in just days while improving dry, flaky skin by restoring the skin's barrier function and increasing moisture retention. PyratineXR offers an option for inflammatory skin conditions such as rosacea, acne, sunburn and razor burn.

PyratineXR is available as a Lotion or Creme through select physicians throughout North America. Senetek plans to introduce three new products for PyratineXR later this year. For more information or to find a PyratineXR Physicians Network doctor, call 1-888-467-9728 or visit www.PyratineXR.com. To watch a brief video news segment about PyratineXR, visit www.youtube.com/watch?v=i8oa3N99e_o.